Cargando…

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib

INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Issei, Kijima, Toshiki, Takada‐Owada, Atsuko, Nakamura, Gaku, Uematsu, Toshitaka, Sakamoto, Kazumasa, Nishihara, Daisaku, Ishida, Kazuyuki, Kamai, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560442/
https://www.ncbi.nlm.nih.gov/pubmed/34755071
http://dx.doi.org/10.1002/iju5.12362
_version_ 1784592933986500608
author Suzuki, Issei
Kijima, Toshiki
Takada‐Owada, Atsuko
Nakamura, Gaku
Uematsu, Toshitaka
Sakamoto, Kazumasa
Nishihara, Daisaku
Ishida, Kazuyuki
Kamai, Takao
author_facet Suzuki, Issei
Kijima, Toshiki
Takada‐Owada, Atsuko
Nakamura, Gaku
Uematsu, Toshitaka
Sakamoto, Kazumasa
Nishihara, Daisaku
Ishida, Kazuyuki
Kamai, Takao
author_sort Suzuki, Issei
collection PubMed
description INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left‐sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8(+) T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence‐free without any additional treatment for eight months. CONCLUSION: For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery.
format Online
Article
Text
id pubmed-8560442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85604422021-11-08 A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib Suzuki, Issei Kijima, Toshiki Takada‐Owada, Atsuko Nakamura, Gaku Uematsu, Toshitaka Sakamoto, Kazumasa Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao IJU Case Rep Case Reports INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left‐sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8(+) T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence‐free without any additional treatment for eight months. CONCLUSION: For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery. John Wiley and Sons Inc. 2021-08-24 /pmc/articles/PMC8560442/ /pubmed/34755071 http://dx.doi.org/10.1002/iju5.12362 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Suzuki, Issei
Kijima, Toshiki
Takada‐Owada, Atsuko
Nakamura, Gaku
Uematsu, Toshitaka
Sakamoto, Kazumasa
Nishihara, Daisaku
Ishida, Kazuyuki
Kamai, Takao
A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
title A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
title_full A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
title_fullStr A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
title_full_unstemmed A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
title_short A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
title_sort case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560442/
https://www.ncbi.nlm.nih.gov/pubmed/34755071
http://dx.doi.org/10.1002/iju5.12362
work_keys_str_mv AT suzukiissei acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT kijimatoshiki acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT takadaowadaatsuko acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT nakamuragaku acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT uematsutoshitaka acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT sakamotokazumasa acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT nishiharadaisaku acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT ishidakazuyuki acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT kamaitakao acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT suzukiissei caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT kijimatoshiki caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT takadaowadaatsuko caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT nakamuragaku caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT uematsutoshitaka caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT sakamotokazumasa caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT nishiharadaisaku caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT ishidakazuyuki caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib
AT kamaitakao caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib